Our magazine is free!

for living with diabetes

Novo Nordisk launches Xultophy

This month (Jan 2015) Switzerland was the first country to launch Novo Nordisk’s Xultophy (IDegLira) for people with Type 2 diabetes. Xultophy is the first combination of a basal insulin (Tresiba, insulin degludec) and a GLP-1 analogue (Victoza, liraglutide). Xultophy is administered as a once-daily single injection independently of meals. It is intended for use in adults with Type 2 diabetes that are inadequately controlled with oral glucose-lowering treatments when these are used alone or together with basal insulin. For people with type 2 diabetes uncontrolled on basal insulin, Xultophy has demonstrated a significant 1.9% HbA1c reduction, mean weight loss of 2.7 kg and a low rate of hypoglycaemia (low blood sugar) comparable to insulin degludec. Novo Nordisk expects to make Xultophy available in other countries throughout Europe in 2015.

This news item first appeared in our free-to-receive online magazine. We cover diabetes news, diabetes management equipment (diabetes kit) and food news for the diabetic diet. Go to the top of this page to sign up – we just need your email address.

Open publication

Sign up to our Magazine »

Leave a Comment

Submit Comment »

No Comments Yet!


nl-imageDirect to your inbox, our

free online magazine.

Sign up for the Desang Diabetes Magazine for new products, special offers and news.

*We will never email you more often than once a week (usually once a month). You can easily unsubscribe at any time. It’s finger-pricking good!

Close Don't show again